BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-778@pharmaconomics
DTSTAMP:20260707T041328Z
DTSTART;VALUE=DATE:20260412
DTEND;VALUE=DATE:20260413
SUMMARY:PMVP Phase 1 — rezatapopt
DESCRIPTION:Phase 1 trial results for rezatapopt in platinum-resistant/refractory ovarian cancer are due Apr 12\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/778
URL:https://pharmaconomics.com/e/778
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PMVP catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR